Results of a Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) Phase 1b study in T cell lymphomas have been accepted for poster presentation at the prestigious American Society of Hematology (ASH) Annual Meeting in December.
The ASH Annual Meeting, which is in its 65th year, will take place on December 9-12, 2023, in San Diego, California.
Regarded as the world's largest and most exhaustive conference on haematology, the ASH Annual Meeting serves as a global forum for physicians, industry stakeholders and researchers to converse on the newest breakthroughs and innovations in the field of haematological diseases.
In the previous year, the event attracted a robust participation, with more than 25,000 attendees.
An honour and validation
The forum is validation of PTX’s ongoing work in clinical stage oncology and its development of personalised therapies for cancer.
Prescient Therapeutics managing director and CEO Steven Yatomi-Clarke said, “It is a huge honour to have our abstract presented at the world’s most prestigious haematology conference.
"This is a validation of the quality and relevance of the clinical data we are generating in T cell lymphomas, which is an area of unmet clinical need. It is also a testament to the hard work by the Prescient team and our clinical collaborators.
“Prescient looks forward to presenting this data at ASH and will release this data to the market concurrently.”